LNDC Landec Corp.

Landec Corporation Sets Fourth Quarter and Fiscal Year-End 2018 Conference Call for August 1, 2018 at 8 a.m. PT and Earnings Release set for July 31, 2018 After Market

Landec Corporation Sets Fourth Quarter and Fiscal Year-End 2018 Conference Call for August 1, 2018 at 8 a.m. PT and Earnings Release set for July 31, 2018 After Market

SANTA CLARA, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq:LNDC), a leading innovator of diversified health and wellness solutions within the branded natural food and biomaterial markets, will hold a conference call on Wednesday August 1, 2018 at 8 a.m. Pacific time to discuss its results for the fourth quarter and fiscal year-end 2018. Financial results will be reported for the 2018 fiscal fourth quarter and fiscal year ended May 27, 2018 after market close on July 31, 2018.

Landec's President and CEO, Molly A. Hemmeter, will host the Conference Call with Gregory S. Skinner, Vice President and CFO. A question and answer period will follow the presentation.

Date: Wednesday August 1, 2018

Time: 8 a.m. Pacific time (11 a.m. Eastern time)

Toll Free Participant Dial-in Number: (844) 860-6243

U.S. and International Toll Number: (661) 378-9884

Conference ID: 8777468

Webcast:

The webcast will be available for 30 days through August 31, 2018.

A replay of the teleconference will be available for one week until midnight Eastern Time on Wednesday August 8, 2018.

Toll free replay dial in: (855) 859-2056

International replay: (404) 537-3406

Replay passcode: 8777468

About Landec Corporation

Landec Corporation (Nasdaq:LNDC) is a leading innovator of diversified health and wellness solutions within the packaged natural food and biomaterial markets. Apio is a leader in branded, packaged fresh vegetables in North America, utilizing its proprietary BreatheWay® packaging technology to naturally extend the shelf life of fresh produce. Apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the Eat Smart® brand to consumers through club and retail grocery stores. Extending its reach into adjacent natural food products, Landec recently acquired O Olive Oil, an organic and natural producer and marketer of olive oils and vinegars under the O® brand. Lifecore Biomedical, Landec’s biomaterial business, is a fully integrated Contract Development and Manufacturing Organization (CDMO) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for FDA regulated medical devices and drugs to customers for applications in a wide array of markets including Ophthalmic, Orthopedic and Oncology. For more information about the company, visit Landec’s website at .

Contact Information: 
  
At the Company:Investor Relations:
Gregory S. SkinnerJohn Mills, Partner
Vice President Finance and CFO(646) 277-1254
(650) 261-3677
EN
10/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovat...

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clini...

 PRESS RELEASE

Lifecore Biomedical to Participate at DCAT Week 2026

Lifecore Biomedical to Participate at DCAT Week 2026 CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore’s participation are as follows: DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and n...

 PRESS RELEASE

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to tw...

 PRESS RELEASE

Lifecore Biomedical to be Added to Nasdaq Biotech Index

Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...

 PRESS RELEASE

Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer  Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch